DEGRO practical guidelines for radiotherapy of breast cancer IV

作者：Wenz Frederik^*; Sperk Elena; Budach Wilfried; Dunst Juergen; Feyer Petra; Fietkau Rainer; Haase Wulf; Harms Wolfgang; Piroth Marc D; Sautter Bihl Marie Luise; Sedlmayer Felix; Souchon Rainer; Fussl Christoph; Sauer Rolf

来源：Strahlentherapie und Onkologie, 2014, 190(8): 705-714.

DOI：10.1007/s00066-014-0687-0

• Postmastectomy radiotherapy (PMRT)
• Breast cancer
• Guideline
• Mastectomy
• Risk factors

Background and purpose. Since the last recommendations from the Breast Cancer Expert Panel of the German Society for Radiation Oncology (DEGRO) in 2008, evidence for the effectiveness of postmastectomy radiotherapy (PMRT) has grown. This growth is based on updates of the national S3 and international guidelines, as well as on new data and meta-analyses. New aspects were considered when updating the DEGRO recommendations. %26lt;br%26gt;Methods. The authors performed a comprehensive survey of the literature. Data from recently published (meta-) analyses, randomized clinical trials and international cancer societies%26apos; guidelines yielding new aspects compared to 2008 were reviewed and discussed. New aspects were included in the current guidelines. Specific issues relating to particular PMRT constellations, such as the presence of risk factors (lymphovascular invasion, blood vessel invasion, positive lymph node ratio %26gt; 20 %, resection margins %26lt; 3 mm, G3 grading, young age/premenopausal status, extracapsular invasion, negative hormone receptor status, invasive lobular cancer, size %26gt; 2 cm or a combination of %26gt;= 2 risk factors) and 1-3 positive lymph nodes are emphasized. %26lt;br%26gt;Results. The evidence for improved overall survival and local control following PMRT for T4 tumors, positive resection margins, %26gt; 3 positive lymph nodes and in T3 N0 patients with risk factors such as lymphovascular invasion, G3 grading, close margins, and young age has increased. Recently identi-fied risk factors such as invasive lobular subtype and negative hormone receptor status were included. For patients with 1-3 positive lymph nodes, the recommendation for PMRT has reached the 1a level of evidence. %26lt;br%26gt;Conclusion. PMRT is mandatory in patients with T4 tumors and/or positive lymph nodes and/or positive resection margins. PMRT should be strongly considered in patients with T3 N0 tumors and risk factors, particularly when two or more risk factors are present.

• 出版日期2014-8